-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Micreos announced that it has received 32 million euros in funding to further develop its innovative endolysins technology platform
.
The platform will not affect beneficial microorganisms like traditional antibiotics, but only target and kill harmful bacteria
The microbiome in the human body is vital to body function and plays an important role in maintaining the stability of the immune system.
However, the emergence of antibiotics has broken this balance
.
Most antibiotics are "we do not distinguish between the enemy and the enemy".
Micreos' strategy is to borrow endolysins produced by nature
.
Endolysin is a compound released by phage to dissolve the cell wall from inside the bacteria
▲Bacteriophages use endolysin to destroy bacterial cell walls (picture source: reference [2])
Among the two current lead drugs, XZ.
700 targets to kill Staphylococcus aureus, including antibiotic-resistant methicillin-resistant Staphylococcus aureus (MRSA), while retaining the epidermis that is beneficial to the skin and conducive to wound healing Staphylococcus epidermidis
.
SP.
Reference materials:
[1] Micreos secures €32 million for its endolysin-based platform as sustainable alternative to antibiotics.
[2] Murray et al.